nach oben

Die Diabetologie

Erschienen in:

24.01.2023 | Diabetische Nephropathie | Leitthema

Aktuelles zu diagnostischen und prognostischen Biomarkern einer diabetischen Nephropathie

verfasst von: Carolin Herzog, Katrin Bose, Maximilian J. Ganz, Peter R. Mertens, Florian G. Scurt

Erschienen in: Die Diabetologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die diabetische Nephropathie (DN) stellt eine häufige Komplikation des Diabetes mellitus dar, die im Verlauf bei zu später Diagnostik oder unzureichender Therapie in einer terminalen Niereninsuffizienz mit Dialysepflichtigkeit mündet. Klassischerweise wird die diabetische Nephropathie über das Vorhandensein einer Albuminurie definiert. Allerdings kommt es aufgrund des fehlenden tubuloglomerulären Feedbacks bei der diabetischen Nephropathie zur Erhöhung des glomerulären Drucks und einer glomerulären Hyperfiltration, was bereits vor dem Auftreten einer Albuminurie zu strukturellen Veränderungen führt. Diese frühen Schädigungen werden über die herkömmliche Labordiagnostik nicht erfasst und können somit therapeutische Interventionen verzögern. Weiterhin existieren nichtalbuminurische Formen der diabetischen Nephropathie, welche ohne das Auftreten einer Albuminurie mit einer Nierenfunktionsverschlechterung einhergehen. Dementsprechend werden neue diagnostische Marker benötigt, welche in der Lage sind, eine diabetische Nephropathie vor dem Auftreten einer Albuminurie anzuzeigen. In den letzten Jahren wurden zahlreiche glomeruläre und tubuläre Biomarker untersucht, mit welchen die frühe diabetische Nephropathie nachgewiesen werden könnte. Zukunftsweisend könnten dabei sog. „liquid biopsies“, also Muster verschiedener Biomarker, sein.

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https://doi.org/10.1016/j.diabres.2021.109119CrossRefPubMed

Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K et al (2021) Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol 17(11):740–750. https://doi.org/10.1038/s41581-021-00462-yCrossRefPubMed

Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS et al (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316(6):602–610. https://doi.org/10.1001/jama.2016.10924CrossRefPubMedPubMedCentral

National Kidney F (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886. https://doi.org/10.1053/j.ajkd.2012.07.005CrossRef

Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE et al (2009) Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32(8):1497–1502. https://doi.org/10.2337/dc08-2186CrossRefPubMedPubMedCentral

Koye DN, Magliano DJ, Reid CM, Jepson C, Feldman HI, Herman WH et al (2018) Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis 72(5):653–661. https://doi.org/10.1053/j.ajkd.2018.02.364CrossRefPubMed

Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S (2012) Glomerular hyperfiltration in prediabetes and prehypertension. Nephrol Dial Transplant 27(5):1821–1825. https://doi.org/10.1093/ndt/gfr651CrossRefPubMed

Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F et al (2012) Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35(10):2061–2068. https://doi.org/10.2337/dc11-2189CrossRefPubMedPubMedCentral

Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP et al (2017) Single-nephron glomerular filtration rate in healthy adults. N Engl J Med 376(24):2349–2357. https://doi.org/10.1056/NEJMoa1614329CrossRefPubMedPubMedCentral

10.

Mogensen CE, Christensen CK, Vittinghus E (1983) The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(2):64–78. https://doi.org/10.2337/diab.32.2.s64CrossRefPubMed

11.

Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28(4):1023–1039. https://doi.org/10.1681/ASN.2016060666CrossRefPubMedPubMedCentral

12.

Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241(1):F85–93. https://doi.org/10.1152/ajprenal.1981.241.1.F85CrossRefPubMed

13.

Furuichi K, Shimizu M, Yamanouchi M, Hoshino J, Sakai N, Iwata Y et al (2020) Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diabetes Res Care 8(1):e1157. https://doi.org/10.1136/bmjdrc-2019-001157CrossRefPubMedPubMedCentral

14.

Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH (2001) Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24(11):1972–1977. https://doi.org/10.2337/diacare.24.11.1972CrossRefPubMed

15.

Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O (2004) Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19(11):2784–2788. https://doi.org/10.1093/ndt/gfh470CrossRefPubMed

16.

Kramer HJ, Nguyen QD, Curhan G, Hsu CY (2003) Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289(24):3273–3277. https://doi.org/10.1001/jama.289.24.3273CrossRefPubMed

17.

Bash LD, Selvin E, Steffes M, Coresh J, Astor BC (2008) Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: atherosclerosis risk in communities (ARIC) study. Arch Intern Med 168(22):2440–2447. https://doi.org/10.1001/archinte.168.22.2440CrossRefPubMedPubMedCentral

18.

Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM et al (2008) Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3(2):348–354. https://doi.org/10.2215/cjn.02870707CrossRefPubMedPubMedCentral

19.

Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA et al (2010) Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care 14(3):R82. https://doi.org/10.1186/cc9004CrossRefPubMedPubMedCentral

20.

Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C (2020) Acute kidney injury following acute pancreatitis (AP-AKI): definition, pathophysiology, diagnosis and therapy. Z Gastroenterol 58(12):1241–1266. https://doi.org/10.1055/a-1255-3413CrossRefPubMed

21.

Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C (2020) Paradigm shift in understanding acute kidney injury in patients with chronic liver disease: from pathophysiology to defining disease entities. Z Gastroenterol 58(3):254–266. https://doi.org/10.1055/a-1088-1582CrossRefPubMed

22.

Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C (2021) Chronic kidney injury in patients with liver diseases—reappraising pathophysiology and treatment options. Z Gastroenterol 59(6):560–579. https://doi.org/10.1055/a-1402-1502CrossRefPubMed

23.

Doi K, Yuen PS, Eisner C, Hu X, Leelahavanichkul A, Schnermann J et al (2009) Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol 20(6):1217–1221. https://doi.org/10.1681/asn.2008060617CrossRefPubMedPubMedCentral

24.

Schetz M, Gunst J, Van den Berghe G (2014) The impact of using estimated GFR versus creatinine clearance on the evaluation of recovery from acute kidney injury in the ICU. Intensive Care Med 40(11):1709–1717. https://doi.org/10.1007/s00134-014-3487-1CrossRefPubMed

25.

Andreev E, Koopman M, Arisz L (1999) A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246(3):247–252. https://doi.org/10.1046/j.1365-2796.1999.00515.xCrossRefPubMed

26.

Waikar SS, Bonventre JV (2009) Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 20(3):672–679. https://doi.org/10.1681/asn.2008070669CrossRefPubMedPubMedCentral

27.

Zhang X, Rule AD, McCulloch CE, Lieske JC, Ku E, Hsu C‑Y (2020) Tubular secretion of creatinine and kidney function: an observational study. BMC Nephrol 21(1):108. https://doi.org/10.1186/s12882-020-01736-6CrossRefPubMedPubMedCentral

28.

Herget-rosenThal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O et al (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66(3):1115–1122. https://doi.org/10.1111/j.1523-1755.2004.00861.xCrossRefPubMed

29.

Sharma A, Mucino MJ, Ronco C (2014) Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract 127(1):94–100. https://doi.org/10.1159/000363721CrossRefPubMed

30.

Scurt FG, Morgenroth R, Bose K, Mertens PR, Chatzikyrkou C (2022) Pr-AKI: acute kidney injury in pregnancy—etiology, diagnostic workup, management. Geburtshilfe Frauenheilkd 82(3):297–316. https://doi.org/10.1055/a-1666-0483CrossRefPubMedPubMedCentral

31.

Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F et al (2013) The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 84(1):164–173. https://doi.org/10.1038/ki.2013.47CrossRefPubMed

32.

Haines RW, Zolfaghari P, Wan Y, Pearse RM, Puthucheary Z, Prowle JR (2019) Elevated urea-to-creatinine ratio provides a biochemical signature of muscle catabolism and persistent critical illness after major trauma. Intensive Care Med 45(12):1718–1731. https://doi.org/10.1007/s00134-019-05760-5CrossRefPubMed

33.

Chopra D, Rosenberg M, Moayyedi P, Narula N (2020) Is blood urea concentration an independent predictor of positive endoscopic findings in presumed upper gastrointestinal bleeding? Dig Dis 38(1):77–84. https://doi.org/10.1159/000501549CrossRefPubMed

34.

Tenstad O, Roald AB, Grubb A, Aukland K (1996) Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 56(5):409–414. https://doi.org/10.3109/00365519609088795CrossRefPubMed

35.

De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S et al (2014) Creatinine- versus cystatine C‑based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 59(4):1522–1531. https://doi.org/10.1002/hep.26886CrossRefPubMed

36.

Jo SK, Yang J, Hwang SM, Lee MS, Park SH (2019) Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis. Sci Rep 9(1):14508. https://doi.org/10.1038/s41598-019-51053-8CrossRefPubMedPubMedCentral

37.

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C‑based equations to estimate GFR without race. N Engl J Med 385(19):1737–1749. https://doi.org/10.1056/NEJMoa2102953CrossRefPubMedPubMedCentral

38.

Aldenbratt A, Lindberg C, Johannesson E, Hammarsten O, Svensson MK (2022) Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine? J Nephrol 35(2):493–503. https://doi.org/10.1007/s40620-021-01122-xCrossRefPubMed

39.

Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC et al (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65(4):1416–1421. https://doi.org/10.1111/j.1523-1755.2004.00517.xCrossRefPubMed

40.

Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C (2003) Impact of thyroid dysfunction on serum cystatin C. Kidney Int 63(5):1944–1947. https://doi.org/10.1046/j.1523-1755.2003.00925.xCrossRefPubMed

41.

Yokoyama H, Inoue T, Node K (2009) Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. Diabetes Res Clin Pract 83(1):77–82. https://doi.org/10.1016/j.diabres.2008.09.049CrossRefPubMed

42.

Zhai JL, Ge N, Zhen Y, Zhao Q, Liu C (2016) Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure. Clin Lab 62(1):203–207. https://doi.org/10.7754/clin.lab.2015.150701CrossRefPubMed

43.

Kanauchi M, Nishioka H, Hashimoto T, Dohi K (1995) Diagnostic significance of urinary transferrin in diabetic nephropathy. Nihon Jinzo Gakkai Shi 37(11):649–654PubMed

44.

Uwaezuoke SN (2017) The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renovasc Dis 10:221–231. https://doi.org/10.2147/IJNRD.S143186CrossRefPubMedPubMedCentral

45.

Sánchez-Hidalgo JJ, Suárez-Cuenca JA, Lozano-Nuevo JJ, García-López VH, Leal-Gutiérrez MG, León-Angel SA et al (2021) Urine transferrin as an early endothelial dysfunction marker in type 2 diabetic patients without nephropathy: a case control study. Diabetol Metab Syndr 13(1):128. https://doi.org/10.1186/s13098-021-00745-1CrossRefPubMedPubMedCentral

46.

Yaqoob M, McClelland P, Patrick AW, Stevenson A, Mason H, Bell GM (1995) Tubular damage in microalbuminuric patients with primary glomerulonephritis and diabetic nephropathy. Ren Fail 17(1):43–49. https://doi.org/10.3109/08860229509036374CrossRefPubMed

47.

Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T et al (2004) Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 27(5):1176–1181. https://doi.org/10.2337/diacare.27.5.1176CrossRefPubMed

48.

Gudehithlu KP, Hart P, Joshi A, Garcia-Gomez I, Cimbaluk DJ, Dunea G et al (2019) Urine exosomal ceruloplasmin: a potential early biomarker of underlying kidney disease. Clin Exp Nephrol 23(8):1013–1021. https://doi.org/10.1007/s10157-019-01734-5CrossRefPubMed

49.

Mahendran KB, Bhaskar MV, Santha K, Inmozhi R, Perumal KK (2016) Plasma and urinary type IV collagen levels for early detection of nephropathy in type 2 diabetes mellitus. Int J Health Sci (Qassim) 10(4):492–498PubMed

50.

Araki S, Haneda M, Koya D, Isshiki K, Kume S, Sugimoto T et al (2010) Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 33(8):1805–1810. https://doi.org/10.2337/dc10-0199CrossRefPubMedPubMedCentral

51.

Miyake H, Nagashima K, Yagi H, Onigata K (1993) Urinary laminin P1 as an index of glycemic control in children with insulin-dependent diabetes mellitus. Diabetes Res 23(3):131–138PubMed

52.

Banu N, Hara H, Okamura M, Egusa G, Yamakido M (1995) Urinary excretion of type IV collagen and laminin in the evaluation of nephropathy in NIDDM: comparison with urinary albumin and markers of tubular dysfunction and/or damage. Diabetes Res Clin Pract 29(1):57–67. https://doi.org/10.1016/0168-8227(95)01119-xCrossRefPubMed

53.

Furumatsu Y, Nagasawa Y, Shoji T, Yamamoto R, Iio K, Matsui I et al (2011) Urinary type IV collagen in nondiabetic kidney disease. Nephron Clin Pract 117(2):c160–6. https://doi.org/10.1159/000319794CrossRefPubMed

54.

Kanauchi M, Nishioka H, Dohi K (1995) Diagnostic significance of urinary fibronectin in diabetic nephropathy. Nihon Jinzo Gakkai Shi 37(2):127–133PubMed

55.

Malmström PU, Larsson A, Johansson S (1993) Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer. Br J Urol 72(3):307–310. https://doi.org/10.1111/j.1464-410x.1993.tb00723.xCrossRefPubMed

56.

Saito N, Nishimura H, Kameoka S (2008) Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep 1(1):77–81PubMed

57.

Kim BS, Chen J, Weinstein T, Noiri E, Goligorsky MS (2002) VEGF expression in hypoxia and hyperglycemia: reciprocal effect on branching angiogenesis in epithelial-endothelial co-cultures. J Am Soc Nephrol 13(8):2027–2036. https://doi.org/10.1097/01.asn.0000024436.00520.d8CrossRefPubMed

58.

Day RT, Cavaglieri Rde C, Tabatabaimir H, Mantravadi V, Lee MJ, Barnes JL et al (2010) Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal 22(12):1849–1857. https://doi.org/10.1016/j.cellsig.2010.07.012CrossRefPubMedPubMedCentral

59.

Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH et al (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med 21(6):545–551. https://doi.org/10.1111/j.1464-5491.2004.01200.xCrossRefPubMed

60.

Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM et al (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT‑1 in diabetic nephropathy. Kidney Int 67(1):167–177. https://doi.org/10.1111/j.1523-1755.2005.00067.xCrossRefPubMed

61.

Dağdeviren Çakır A, Saygılı SK, Canpolat N, Konukoğlu D, Turan H, Çalışkan S et al (2021) Elevated urinary VEGF‑A, transferrin, and angiotensinogen levels in normoalbuminuric children and adolescents with type 1 diabetes: can they be early markers of diabetic kidney disease? Horm Res Paediatr 94(11):426–432. https://doi.org/10.1159/000521447CrossRefPubMed

62.

Crew JP, O’Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161(3):799–804CrossRefPubMed

63.

Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ et al (2005) Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 192(3):734–741. https://doi.org/10.1016/j.ajog.2004.12.052CrossRefPubMed

64.

Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N (2018) Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynecol J 29(7):961–966. https://doi.org/10.1007/s00192-017-3547-5CrossRefPubMed

65.

Kotajima N, Kimura T, Kanda T, Obata K, Kuwabara A, Fukumura Y et al (2000) Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus. J Diabetes Complications 14(1):13–17. https://doi.org/10.1016/s1056-8727(00)00064-7CrossRefPubMed

66.

Fiseha T (2015) Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res 3:16. https://doi.org/10.1186/s40364-015-0042-3CrossRefPubMedPubMedCentral

67.

Adler SG, Feld S, Striker L, Striker G, LaPage J, Esposito C et al (2000) Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int 57(5):2084–2092. https://doi.org/10.1046/j.1523-1755.2000.00058.xCrossRefPubMed

68.

Sthaneshwar P, Chan SP (2010) Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol 32(1):43–47PubMed

69.

Hayashi Y, Makino H, Ota Z (1992) Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med 9(4):366–370. https://doi.org/10.1111/j.1464-5491.1992.tb01798.xCrossRefPubMed

70.

Kuboki K, Tada H, Shin K, Oshima Y, Isogai S (1993) Relationship between urinary excretion of fibronectin degradation products and proteinuria in diabetic patients, and their suppression after continuous subcutaneous heparin infusion. Diabetes Res Clin Pract 21(1):61–66. https://doi.org/10.1016/0168-8227(93)90098-pCrossRefPubMed

71.

Pelle MC, Provenzano M, Busutti M, Porcu CV, Zaffina I, Stanga L et al (2022) Up-date on diabetic nephropathy. Life. https://doi.org/10.3390/life12081202CrossRefPubMedPubMedCentral

72.

Zhang J, Liu J, Qin X (2018) Advances in early biomarkers of diabetic nephropathy. Rev Assoc Med Bras 64(1):85–92. https://doi.org/10.1590/1806-9282.64.01.85CrossRefPubMed

73.

Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10(12):2569–2576. https://doi.org/10.1681/asn.V10122569CrossRefPubMed

74.

Vallon V, Thomson SC (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 16(6):317–336. https://doi.org/10.1038/s41581-020-0256-yCrossRefPubMedPubMedCentral

75.

Huang H‑C, Preisig PA (2000) G1 kinases and transforming growth factor‑β; signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int 58(1):162–172. https://doi.org/10.1046/j.1523-1755.2000.00151.xCrossRefPubMed

76.

Nayak BK, Shanmugasundaram K, Friedrichs WE, Cavaglierii RC, Patel M, Barnes J et al (2016) HIF‑1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes 65(5):1387–1397. https://doi.org/10.2337/db15-0519CrossRefPubMedPubMedCentral

77.

Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H et al (2019) Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep 9(1):14754. https://doi.org/10.1038/s41598-019-51343-1CrossRefPubMedPubMedCentral

78.

Hsu CY, Xie D, Waikar SS, Bonventre JV, Zhang X, Sabbisetti V et al (2017) Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 91(1):196–203. https://doi.org/10.1016/j.kint.2016.09.003CrossRefPubMed

79.

Sancho-Martínez SM, Blanco-Gozalo V, Quiros Y, Prieto-García L, Montero-Gómez MJ, Docherty NG et al (2020) Impaired tubular reabsorption is the main mechanism explaining increases in urinary NGAL excretion following acute kidney injury in rats. Toxicol Sci 175(1):75–86. https://doi.org/10.1093/toxsci/kfaa029CrossRefPubMed

80.

Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J et al (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115(3):610–621. https://doi.org/10.1172/jci23056CrossRefPubMedPubMedCentral

81.

Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y et al (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 75(3):285–294. https://doi.org/10.1038/ki.2008.499CrossRefPubMed

82.

Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM et al (2011) The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 17(2):216–222. https://doi.org/10.1038/nm.2290CrossRefPubMedPubMedCentral

83.

Kapoula GV, Kontou PI, Bagos PG (2019) Diagnostic accuracy of neutrophil gelatinase-associated lipocalin for predicting early diabetic nephropathy in patients with type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis. J Appl Lab Med 4(1):78–94. https://doi.org/10.1373/jalm.2018.028530CrossRefPubMed

84.

Fu WJ, Li BL, Wang SB, Chen ML, Deng RT, Ye CQ et al (2012) Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract 95(1):105–109. https://doi.org/10.1016/j.diabres.2011.09.031CrossRefPubMed

85.

Şen S, Özalp Kızılay D, Taneli F, Özen Ç, Ertan P, Özunan İ et al (2021) Urinary NGAL is a potential biomarker for early renal injury in insulin resistant obese non-diabetic children. J Clin Res Pediatr Endocrinol 13(4):400–407. https://doi.org/10.4274/jcrpe.galenos.2021.2021.0020CrossRefPubMedPubMedCentral

86.

Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, Hillien StSA et al (2021) Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: a prospective study. Clin Transl Gastroenterol 12(5):e359. https://doi.org/10.14309/ctg.0000000000000359CrossRefPubMedPubMedCentral

87.

Jahaj E, Vassiliou AG, Pratikaki M, Gallos P, Mastora Z, Dimopoulou I et al (2021) Serum neutrophil gelatinase-associated lipocalin (NGAL) could provide better accuracy than creatinine in predicting acute kidney injury development in critically ill patients. J Clin Med. https://doi.org/10.3390/jcm10225379CrossRefPubMedPubMedCentral

88.

Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S et al (2012) Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 60(4):339–345. https://doi.org/10.1016/j.jacc.2012.04.017CrossRefPubMed

89.

Eilenberg W, Stojkovic S, Kaider A, Piechota-Polanczyk A, Nanobachvili J, Domenig CM et al (2019) Neutrophil gelatinase associated lipocalin (NGAL) for identification of unstable plaques in patients with asymptomatic carotid stenosis. Eur J Vasc Endovasc Surg 57(6):768–777. https://doi.org/10.1016/j.ejvs.2018.12.029CrossRefPubMed

90.

Li C, Zhang Z, Peng Y, Gao H, Wang Y, Zhao J et al (2019) Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS ONE 14(8):e220841. https://doi.org/10.1371/journal.pone.0220841CrossRefPubMedPubMedCentral

91.

Bergquist M, Samuelsson L, Larsson A, Tydén J, Johansson J, Lipcsey M (2020) TNFR1, TNFR2, neutrophil gelatinase-associated lipocalin and heparin binding protein in identifying sepsis and predicting outcome in an intensive care cohort. Sci Rep 10(1):15350. https://doi.org/10.1038/s41598-020-72003-9CrossRefPubMedPubMedCentral

92.

Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290(2):F517–29. https://doi.org/10.1152/ajprenal.00291.2005CrossRefPubMed

93.

Tu Y, Wang H, Sun R, Ni Y, Ma L, Xv F et al (2014) Urinary netrin‑1 and KIM‑1 as early biomarkers for septic acute kidney injury. Ren Fail 36(10):1559–1563. https://doi.org/10.3109/0886022X.2014.949764CrossRefPubMed

94.

Khreba NA, Abdelsalam M, Wahab AM, Sanad M, Elhelaly R, Adel M et al (2019) Kidney injury molecule 1 (KIM-1) as an early predictor for acute kidney injury in post-cardiopulmonary bypass (CPB) in open heart surgery patients. Int J Nephrol 2019:6265307. https://doi.org/10.1155/2019/6265307CrossRefPubMedPubMedCentral

95.

Zhang C, Wang H, Tong Z, Zhang C, Wang Y, Yang H et al (2020) The diagnostic and prognostic values of serum and urinary kidney injury molecule‑1 and neutrophil gelatinase-associated lipocalin in sepsis induced acute renal injury patients. Eur Rev Med Pharmacol Sci 24(10):5604–5617PubMed

96.

Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR et al (2010) Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 27(10):1144–1150. https://doi.org/10.1111/j.1464-5491.2010.03083.xCrossRefPubMed

97.

Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH et al (2011) Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule‑1, and N‑acetyl-β-D-glucosaminidase. Kidney Int 79(4):464–470. https://doi.org/10.1038/ki.2010.404CrossRefPubMed

98.

Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlström EH, Thorn LM et al (2015) Kidney injury molecule‑1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care 38(6):1130–1137. https://doi.org/10.2337/dc14-2330CrossRefPubMed

99.

de Carvalho JAM, Tatsch E, Hausen BS, Bollick YS, Moretto MB, Duarte T et al (2016) Urinary kidney injury molecule‑1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem 49(3):232–236. https://doi.org/10.1016/j.clinbiochem.2015.10.016CrossRefPubMed

100.

Nielsen SE, Reinhard H, Zdunek D, Hess G, Gutiérrez OM, Wolf M et al (2012) Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 97(1):71–76. https://doi.org/10.1016/j.diabres.2012.02.007CrossRefPubMed

101.

Satirapoj B, Aramsaowapak K, Tangwonglert T, Supasyndh O (2016) Novel tubular biomarkers predict renal progression in type 2 diabetes mellitus: a prospective cohort study. J Diabetes Res 2016:3102962. https://doi.org/10.1155/2016/3102962CrossRefPubMedPubMedCentral

102.

Satirapoj B, Pooluea P, Nata N, Supasyndh O (2019) Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: a prospective cohort study. J Diabetes Complicat 33(9):675–681. https://doi.org/10.1016/j.jdiacomp.2019.05.013CrossRef

103.

Panduru NM, Forsblom C, Saraheimo M, Thorn L, Bierhaus A, Humpert PM et al (2013) Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 36(7):2077–2083. https://doi.org/10.2337/dc12-1868CrossRefPubMedPubMedCentral

104.

Thi TND, Gia BN, Thi HLL, Thi TNC, Thanh HP (2020) Evaluation of urinary L‑FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem 39(2):224–230. https://doi.org/10.2478/jomb-2019-0037CrossRefPubMedPubMedCentral

105.

Gonzalez J, Jatem E, Roig J, Valtierra N, Ostos E, Abo A et al (2022) Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfac185CrossRefPubMed

106.

Parr SK, Clark AJ, Bian A, Shintani AK, Wickersham NE, Ware LB et al (2015) Urinary L‑FABP predicts poor outcomes in critically ill patients with early acute kidney injury. Kidney Int 87(3):640–648. https://doi.org/10.1038/ki.2014.301CrossRefPubMed

107.

Suzuki G, Ichibayashi R, Yamamoto S, Nakamichi Y, Watanabe M, Honda M (2019) Clinical significance of urinary L‑FABP in the emergency department. Int J Emerg Med 12(1):24. https://doi.org/10.1186/s12245-019-0244-9CrossRefPubMedPubMedCentral

108.

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T et al (2006) Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284(1):175–182. https://doi.org/10.1007/s11010-005-9047-9CrossRefPubMed

109.

Sunayama T, Yatsu S, Matsue Y, Dotare T, Maeda D, Ishiwata S et al (2022) Urinary liver-type fatty acid-binding protein as a prognostic marker in patients with acute heart failure. ESC Heart Fail 9(1):442–449. https://doi.org/10.1002/ehf2.13730CrossRefPubMed

110.

Marcovecchio ML, Dalton RN, Turner C, Prevost AT, Widmer B, Amin R et al (2010) Symmetric dimethylarginine, an endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes. Arch Dis Child 95(2):119–124. https://doi.org/10.1136/adc.2009.158394CrossRefPubMed

111.

Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN et al (2015) Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int 88(4):888–896. https://doi.org/10.1038/ki.2015.199CrossRefPubMed

112.

El-Khoury JM, Bunch DR, Hu B, Payto D, Reineks EZ, Wang S (2016) Comparison of symmetric dimethylarginine with creatinine, cystatin C and their eGFR equations as markers of kidney function. Clin Biochem 49(15):1140–1143. https://doi.org/10.1016/j.clinbiochem.2016.07.009CrossRefPubMed

113.

Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM et al (2009) Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75(6):652–660. https://doi.org/10.1038/ki.2008.638CrossRefPubMed

114.

Kokkoris S, Pipili C, Grapsa E, Kyprianou T, Nanas S (2013) Novel biomarkers of acute kidney injury in the general adult ICU: a review. Ren Fail 35(4):579–591. https://doi.org/10.3109/0886022X.2013.773835CrossRefPubMed

115.

Yin C, Wang N (2016) Kidney injury molecule‑1 in kidney disease. Ren Fail 38(10):1567–1573. https://doi.org/10.1080/0886022X.2016.1193816CrossRefPubMed

116.

Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C et al (2014) Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One 9(1):e84131. https://doi.org/10.1371/journal.pone.0084131CrossRefPubMedPubMedCentral

117.

Fazel M, Sarveazad A, Mohamed Ali K, Yousefifard M, Hosseini M (2020) Accuracy of urine kidney injury molecule‑1 in predicting acute kidney injury in children; a systematic review and meta-analysis. Arch Acad Emerg Med 8(1):e44PubMedPubMedCentral

118.

Siddiqui K, Al-Malki B, George TP, Nawaz SS, Rubeaan KA (2019) Urinary N‑acetyl-beta-d-glucosaminidase (NAG) with neutrophil gelatinase-associated lipocalin (NGAL) improves the diagnostic value for proximal tubule damage in diabetic kidney disease. 3 Biotech 9(3):66. https://doi.org/10.1007/s13205-019-1593-zCrossRefPubMedPubMedCentral

119.

Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE et al (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34(4):975–981. https://doi.org/10.2337/dc10-1545CrossRefPubMedPubMedCentral

120.

Mischak H, Delles C, Vlahou A, Vanholder R (2015) Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol 11(4):221–232. https://doi.org/10.1038/nrneph.2014.247CrossRefPubMed

121.

Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S et al (2011) Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 34(3):691–696. https://doi.org/10.2337/dc10-1392CrossRefPubMedPubMedCentral

122.

Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33(6):1320–1324. https://doi.org/10.2337/dc09-2242CrossRefPubMedPubMedCentral

123.

Fiseha T, Tamir Z (2016) Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016:4647685. https://doi.org/10.1155/2016/4647685CrossRefPubMedPubMedCentral

124.

Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S et al (1999) Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 353(9165):1649–1652. https://doi.org/10.1016/S0140-6736(99)01046-6CrossRefPubMed

125.

Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 52(3):812–817. https://doi.org/10.2337/diabetes.52.3.812CrossRefPubMed

126.

Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7(6):327–340. https://doi.org/10.1038/nrneph.2011.51CrossRefPubMed

127.

Lampropoulou IT, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadis G (2014) TNF-alpha and microalbuminuria in patients with type 2 diabetes mellitus. J Diabetes Res 2014:394206. https://doi.org/10.1155/2014/394206CrossRefPubMedPubMedCentral

128.

Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33(3):458–463. https://doi.org/10.1016/s0272-6386(99)70182-4CrossRefPubMed

129.

Navarro JF, Mora C, Maca M, Garca J (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42(1):53–61. https://doi.org/10.1016/s0272-6386(03)00408-6CrossRefPubMed

130.

Zhang D, Ye S, Pan T (2019) The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes. PeerJ 7:e7079. https://doi.org/10.7717/peerj.7079CrossRefPubMedPubMedCentral

131.

Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C et al (2014) Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE cohort. Diabetes Care 37(5):1425–1431. https://doi.org/10.2337/dc13-2580CrossRefPubMed

132.

Fernández-Juárez G, Villacorta Perez J, Luño Fernández JL, Martinez-Martinez E, Cachofeiro V, Barrio Lucia V et al (2017) High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy. Nephrology (Carlton) 22(5):354–360. https://doi.org/10.1111/nep.12781CrossRefPubMed

133.

Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H et al (2000) Usefulness of a highly sensitive urinary and serum IL‑6 assay in patients with diabetic nephropathy. Nephron 85(1):81–85. https://doi.org/10.1159/000045634CrossRefPubMed

134.

Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J et al (2005) Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28(12):2890–2895. https://doi.org/10.2337/diacare.28.12.2890CrossRefPubMed

135.

Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Knowler WC, Rovin BH et al (2015) Urinary monocyte chemoattractant protein‑1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. Nephrol Dial Transplant 30(4):599–606. https://doi.org/10.1093/ndt/gfv012CrossRefPubMedPubMedCentral

136.

Nastase MV, Zeng-Brouwers J, Beckmann J, Tredup C, Christen U, Radeke HH et al (2018) Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney. Matrix Biol 68–69:293–317. https://doi.org/10.1016/j.matbio.2017.12.002CrossRefPubMed

137.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H et al (2019) Systemic inflammation precedes microalbuminuria in diabetes. Kidney Int Rep 4(10):1373–1386. https://doi.org/10.1016/j.ekir.2019.06.005CrossRefPubMedPubMedCentral

138.

Araújo LS, Torquato BGS, da Silva CA, dos Reis Monteiro MLG, dos Santos Martins ALM, da Silva MV et al (2020) Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol 21(1):308. https://doi.org/10.1186/s12882-020-01960-0CrossRefPubMedPubMedCentral

139.

Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K et al (2002) Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes 51(1):238–242. https://doi.org/10.2337/diabetes.51.1.238CrossRefPubMed

140.

Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006) Monocyte chemoattractant protein‑1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69(1):73–80. https://doi.org/10.1038/sj.ki.5000014CrossRefPubMed

141.

Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD (2011) Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol 301(6):F1358–66. https://doi.org/10.1152/ajprenal.00332.2011CrossRefPubMedPubMedCentral

142.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H et al (2022) Monocyte chemoattractant protein‑1 predicts the development of diabetic nephropathy. Diabetes Metab Res Rev 38(2):e3497. https://doi.org/10.1002/dmrr.3497CrossRefPubMed

143.

Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP‑1. Diabetes Care 26(8):2421–2425. https://doi.org/10.2337/diacare.26.8.2421CrossRefPubMed

144.

Feng S‑T, Yang Y, Yang J‑F, Gao Y‑M, Cao J‑Y, Li Z‑L et al (2021) Urinary sediment CCL5 messenger RNA as a potential prognostic biomarker of diabetic nephropathy. Clin Kidney J 15(3):534–544. https://doi.org/10.1093/ckj/sfab186CrossRefPubMedPubMedCentral

145.

Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, Lai V et al (2013) The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56(5):1166–1173. https://doi.org/10.1007/s00125-013-2857-5CrossRefPubMed

146.

Black LM, Lever JM, Agarwal A (2019) Renal inflammation and fibrosis: a double-edged sword. J Histochem Cytochem 67(9):663–681. https://doi.org/10.1369/0022155419852932CrossRefPubMedPubMedCentral

147.

Guiteras R, Flaquer M, Cruzado JM (2016) Macrophage in chronic kidney disease. Clin Kidney J 9(6):765–771. https://doi.org/10.1093/ckj/sfw096CrossRefPubMedPubMedCentral

148.

Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P et al (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102(2):248–260. https://doi.org/10.1016/j.kint.2022.05.012CrossRefPubMed

149.

Toda N, Mukoyama M, Yanagita M, Yokoi H (2018) CTGF in kidney fibrosis and glomerulonephritis. Inflamm Regen 38:14. https://doi.org/10.1186/s41232-018-0070-0CrossRefPubMedPubMedCentral

150.

Zhao L, Zou Y, Liu F (2020) Transforming growth factor-beta1 in diabetic kidney disease. Front Cell Dev Biol 8:187. https://doi.org/10.3389/fcell.2020.00187CrossRefPubMedPubMedCentral

151.

Sureshbabu A, Muhsin SA, Choi ME (2016) TGF-beta signaling in the kidney: profibrotic and protective effects. Am J Physiol Renal Physiol 310(7):F596–F606. https://doi.org/10.1152/ajprenal.00365.2015CrossRefPubMedPubMedCentral

152.

Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX et al (2017) Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis. Medicine 96(15):e6583. https://doi.org/10.1097/md.0000000000006583CrossRefPubMedPubMedCentral

153.

Alicic RZ, Johnson EJ, Tuttle KR (2018) Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv Chronic Kidney Dis 25(2):181–191. https://doi.org/10.1053/j.ackd.2017.12.002CrossRefPubMed

154.

Brown NJ, Vaughan DE, Fogo AB (2002) The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 22(5):399–406. https://doi.org/10.1053/snep.2002.34725CrossRefPubMed

155.

Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA (2018) Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 9(2):119. https://doi.org/10.1038/s41419-017-0135-zCrossRefPubMedPubMedCentral

156.

Hinokio Y, Suzuki S, Hirai M, Suzuki C, Suzuki M, Toyota T (2002) Urinary excretion of 8‑oxo‑7, 8‑dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 45(6):877–882. https://doi.org/10.1007/s00125-002-0831-8CrossRefPubMed

157.

Zhong X, Chung AC, Chen HY, Dong Y, Meng XM, Li R et al (2013) miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56(3):663–674. https://doi.org/10.1007/s00125-012-2804-xCrossRefPubMed

158.

Zanchi C, Macconi D, Trionfini P, Tomasoni S, Rottoli D, Locatelli M et al (2017) MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia 60(6):1114–1125. https://doi.org/10.1007/s00125-017-4248-9CrossRefPubMedPubMedCentral

159.

Li A, Peng R, Sun Y, Liu H, Peng H, Zhang Z (2018) LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling. Cell Death Dis 9(5):461. https://doi.org/10.1038/s41419-018-0527-8CrossRefPubMedPubMedCentral

160.

Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ et al (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 8(4):301–312. https://doi.org/10.1016/s2213-8587(20)30026-7CrossRefPubMed

161.

Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D et al (2017) Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies? Sci Rep 7(1):16915. https://doi.org/10.1038/s41598-017-17083-wCrossRefPubMedPubMedCentral

162.

Fan G, Gong T, Lin Y, Wang J, Sun L, Wei H et al (2021) Urine proteomics identifies biomarkers for diabetic kidney disease at different stages. Clin Proteom 18(1):32. https://doi.org/10.1186/s12014-021-09338-6CrossRef

163.

Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J, Ellis D et al (2013) Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 8(1):e54662. https://doi.org/10.1371/journal.pone.0054662CrossRefPubMedPubMedCentral

164.

Conserva F, Barozzino M, Pesce F, Divella C, Oranger A, Papale M et al (2019) Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of kidney fibrosis in diabetic nephropathy. Sci Rep 9(1):11357. https://doi.org/10.1038/s41598-019-47778-1CrossRefPubMedPubMedCentral

165.

Ghai V, Wu X, Bheda-Malge A, Argyropoulos CP, Bernardo JF, Orchard T et al (2018) Genome-wide profiling of urinary extracellular vesicle microRNAs associated with diabetic nephropathy in type 1 diabetes. Kidney Int Rep 3(3):555–572. https://doi.org/10.1016/j.ekir.2017.11.019CrossRefPubMed

Titel: Aktuelles zu diagnostischen und prognostischen Biomarkern einer diabetischen Nephropathie
verfasst von: Carolin Herzog
Katrin Bose
Maximilian J. Ganz
Peter R. Mertens
Florian G. Scurt
Publikationsdatum: 24.01.2023
Verlag: Springer Medizin
Schlagwörter: Diabetische Nephropathie
Chronische Nierenerkrankung
Diabetes mellitus
Albuminurie
Biomarker
Erschienen in: Die Diabetologie / Ausgabe 3/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01004-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aktuelles zu diagnostischen und prognostischen Biomarkern einer diabetischen Nephropathie

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Metabolisches Gedächtnis bei diabetischer Nierenerkrankung

Therapieoptionen bei diabetischer Nephropathie

Einfache Indizes zur Beurteilung des kardiovaskulären Risikos

DDG Praxisempfehlungen: Nephropathie bei Diabetes

Zeitensprung bei der Diagnostik und Behandlung diabetischer Nierenschäden

DDG Praxisempfehlungen: FINDRISK – Test für Diabetesrisiko

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin